Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice

被引:9
作者
Duan, Wenrui
Gao, Li
Wu, Xin
Hade, Erinn M.
Gao, Jian-Xin
Ding, Haiming
Barsky, Sanford H.
Otterson, Gregory A.
Villalona-Calero, Miguel A.
机构
[1] Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, OH
[2] Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, OH
[3] The Center for Biostatistics, The Ohio State University College of Medicine and Public Health, Columbus, OH
[4] Department of Pathology, The Ohio State University College of Medicine and Public Health, Columbus, OH
[5] Department of Radiology, The Ohio State University College of Medicine and Public Health, Columbus, OH
[6] Department of Pharmacology, The Ohio State University College of Medicine and Public Health, Columbus, OH
来源
PLOS ONE | 2009年 / 4卷 / 05期
关键词
D O I
10.1371/journal.pone.0005563
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Mutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon 273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites. Methodology: To investigate the role of mutant p53 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse model was developed. Rates of lung cancer formation in the transgenic animals and their littermates were evaluated by necropsy studies performed in progressive age cohorts ranging from 4 to 24 months. In order to establish the influence of other common genetic abnormalities in lung tumor formation in the animals, K-Ras gene mutation and p16INK4a (p16) promoter methylation were evaluated in a total of 281 transgenic mice and 189 non-transgenic littermates. Principal Findings: At the age extremes of 4-12 and 22-24 months no differences were observed, with very low prevalence of tumors in animals younger than 12 months, and a relatively high prevalence at age 22 months or older. However, the transgenic mice had a significant higher lung tumor rate than their non-transgenic counterparts during the age of 13-21 months, suggesting an age-related shift in lung tumor formation induced by the lung-specific expression of the human mutant p53. Histopathology suggested a more aggressive nature for the transgenic tumors. Older mice (>13 months) had a significantly higher rate of p16 promoter methylation (17% v 82%). In addition, an age related effect was observed for K-Ras codons 12 or 13 mutations, but not for codon 61 mutations. Conclusions/Significance: These results would suggest that the mutant p53(273H) contributes to an acceleration in the development of spontaneous lung tumors in these mice. Combination with other genetic and epigenetic alterations occurring after the age of 13 months is intimately linked to its oncogenic potential.
引用
收藏
页数:10
相关论文
共 68 条
[41]  
MAZARS R, 1992, CANCER RES, V52, P3918
[42]   TUMOR SUPPRESSOR P53 - ANALYSIS OF WILD-TYPE AND MUTANT P53 COMPLEXES [J].
MILNER, J ;
MEDCALF, EA ;
COOK, AC .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) :12-19
[43]  
MITSUDOMI T, 1992, ONCOGENE, V7, P171
[44]   THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION [J].
MOMAND, J ;
ZAMBETTI, GP ;
OLSON, DC ;
GEORGE, D ;
LEVINE, AJ .
CELL, 1992, 69 (07) :1237-1245
[45]   MECHANISMS OF P53 LOSS IN HUMAN SARCOMAS [J].
MULLIGAN, LM ;
MATLASHEWSKI, GJ ;
SCRABLE, HJ ;
CAVENEE, WK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (15) :5863-5867
[46]   MUTATIONS IN THE P53 GENE OCCUR IN DIVERSE HUMAN-TUMOR TYPES [J].
NIGRO, JM ;
BAKER, SJ ;
PREISINGER, AC ;
JESSUP, JM ;
HOSTETTER, R ;
CLEARY, K ;
BIGNER, SH ;
DAVIDSON, N ;
BAYLIN, S ;
DEVILEE, P ;
GLOVER, T ;
COLLINS, FS ;
WESTON, A ;
MODALI, R ;
HARRIS, CC ;
VOGELSTEIN, B .
NATURE, 1989, 342 (6250) :705-708
[47]   Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome [J].
Olive, KP ;
Tuveson, DA ;
Ruhe, ZC ;
Yin, B ;
Willis, NA ;
Bronson, RT ;
Crowley, D ;
Jacks, T .
CELL, 2004, 119 (06) :847-860
[48]   The IARC TP53 database: New Online mutation analysis and recommendations to users [J].
Olivier, M ;
Eeles, R ;
Hollstein, M ;
Khan, MA ;
Harris, CC ;
Hainaut, P .
HUMAN MUTATION, 2002, 19 (06) :607-614
[49]  
OTTERSON GA, 1995, ONCOGENE, V11, P1211
[50]   Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology [J].
Ozols, Robert F. ;
Herbst, Roy S. ;
Colson, Yolonda L. ;
Gralow, Julie ;
Bonner, James ;
Curran, Walter J., Jr. ;
Eisenberg, Burton L. ;
Ganz, Patricia A. ;
Kramer, Barnett S. ;
Kris, Mark G. ;
Markman, Maurie ;
Mayer, Robert J. ;
Raghavan, Derek ;
Reaman, Gregory H. ;
Sawaya, Raymond ;
Schilsky, Richard L. ;
Schuchter, Lynn M. ;
Sweetenham, John W. ;
Vahdat, Linda T. ;
Winn, Rodger J. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :146-162